Quest Diagnostics Expands Oncology Test Access via Flatiron Health's OncoEMR Integration
Event summary
- Quest Diagnostics integrates Haystack MRD ctDNA test and Comprehensive Genomic Profiling services into Flatiron Health's OncoEMR EHR via a pilot program with American Oncology Network (AON) and other community oncology providers.
- The integration uses the opt-in OncoEMR Molecular Profiling Integration (MPI) ordering feature, enabling 4,700 clinicians across 1,600 community-based cancer care locations to access Quest's services.
- Nearly 200 AON sites now have access to OncoEMR MPI, with a nationwide launch planned for the second half of 2026.
The big picture
Quest Diagnostics' integration with Flatiron Health's OncoEMR reflects a broader trend in healthcare towards digitizing and streamlining oncology diagnostics. This move positions Quest as the largest clinical reference lab to offer such specialized test ordering capabilities within an EHR, potentially setting a new standard for molecular oncology testing workflows.
What we're watching
- Adoption Pace
- Whether the pilot program's success will accelerate Quest Diagnostics' nationwide rollout of OncoEMR MPI integration.
- Competitive Response
- How competitors in clinical reference labs and oncology diagnostics may react to this strategic move by Quest Diagnostics.
- Workflow Efficiency
- The impact of streamlined test ordering and reporting on clinician productivity and patient care outcomes.
Related topics